The prevalence of severe fatigue in rheumatic diseases: an international study

Cécile L Overman, Marianne B Kool, José A P Da Silva, Rinie Geenen, Cécile L Overman, Marianne B Kool, José A P Da Silva, Rinie Geenen

Abstract

Fatigue is a common, disabling, and difficult-to-manage problem in rheumatic diseases. Prevalence estimates of fatigue within rheumatic diseases vary considerably. Data on the prevalence of severe fatigue across multiple rheumatic diseases using a similar instrument is missing. Our aim was to provide an overview of the prevalence of severe fatigue across a broad range of rheumatic diseases and to examine its association with clinical and demographic variables. Online questionnaires were filled out by an international sample of 6120 patients (88 % female, mean age 47) encompassing 30 different rheumatic diseases. Fatigue was measured with the RAND(SF)-36 Vitality scale. A score of ≤35 was taken as representing severe fatigue (90 % sensitivity and 81 % specificity for chronic fatigue syndrome). Severe fatigue was present in 41 to 57 % of patients with a single inflammatory rheumatic disease such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Sjögren's syndrome, psoriatic arthritis, and scleroderma. Severe fatigue was least prevalent in patients with osteoarthritis (35 %) and most prevalent in patients with fibromyalgia (82 %). In logistic regression analysis, severe fatigue was associated with having fibromyalgia, having multiple rheumatic diseases without fibromyalgia, younger age, lower education, and language (French: highest prevalence; Dutch: lowest prevalence). In conclusion, one out of every two patients with a rheumatic disease is severely fatigued. As severe fatigue is detrimental to the patient, the near environment, and society at large, unraveling the underlying mechanisms of fatigue and developing optimal treatment should be top priorities in rheumatologic research and practice.

Keywords: Fatigue; Fibromyalgia; Osteoarthritis; Rheumatic diseases; Rheumatoid arthritis; Vitality.

Figures

Fig. 1
Fig. 1
Prevalence of severe fatigue [RAND(SF)-Vitality score ≤35] in patients with rheumatic diseases. Of the 6120 patients, 6034 had a SF-Vitality score; the number of patients with a missing score ranged per rheumatic disease group from 3 to 16. “A single other rheumatic disease” included all diagnoses which did not reach the minimum of 75 patients to represent a specific rheumatic population. Patients with multiple rheumatic diseases were divided into a group with fibromyalgia and a group without fibromyalgia as one of the diagnoses

References

    1. Stebbings S, Treharne GJ. Fatigue in rheumatic disease: an overview. Int J Clin Rheumatol. 2010;5:487–502. doi: 10.2217/ijr.10.30.
    1. Hewlett S, Nicklin J, Treharne GJ. Fatigue in musculoskeletal conditions. Arthritis Res UK Top Rev. 2008;6:1.
    1. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis. 2004;63:723–729. doi: 10.1136/ard.2003.010769.
    1. Repping-Wuts H, van Riel P, van Achterberg T. Rheumatologists’ knowledge, attitude and current management of fatigue in patients with rheumatoid arthritis(RA) Clin Rheumatol. 2008;27:1549–1555. doi: 10.1007/s10067-008-0967-0.
    1. Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis. 2009;68:1553–1558. doi: 10.1136/ard.2008.098202.
    1. Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology. 2000;39:1249–1254. doi: 10.1093/rheumatology/39.11.1249.
    1. Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis. 1998;57:291–295. doi: 10.1136/ard.57.5.291.
    1. Power JD, Badley EM, French MR, Wall AJ, Hawker GA. Fatigue in osteoarthritis: a qualitative study. BMC Musculoskelet Disord. 2008;9:63. doi: 10.1186/1471-2474-9-63.
    1. Van Tubergen A, Coenen J, Landewé R, et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 2002;47:8–16. doi: 10.1002/art1.10179.
    1. Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology. 2009;48:165–169. doi: 10.1093/rheumatology/ken455.
    1. Dupond JL. Fatigue in patients with rheumatic diseases. Joint Bone Spine. 2011;78:156–160. doi: 10.1016/j.jbspin.2010.05.002.
    1. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum. 2007;57:429–439. doi: 10.1002/art.22611.
    1. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol. 1996;23:1407–1417.
    1. Khlat M, Chau N, Guillemin F, et al. Social disparities in musculoskeletal disorders and associated mental malaise: findings from a population-based survey in France. Scand J Public Health. 2010;38:495–501. doi: 10.1177/1403494810371246.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–610. doi: 10.1002/acr.20140.
    1. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol. 2004;31:695–700.
    1. Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999;58:379–381. doi: 10.1136/ard.58.6.379.
    1. Giles I, Isenberg D. Fatigue in primary Sjögren’s syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis. 2000;59:875–878. doi: 10.1136/ard.59.11.875.
    1. Kool MB, van de Schoot R, López-Chicheri García I, et al. Measurement invariance of the Illness Invalidation Inventory (3*I) across language, rheumatic disease and gender. Ann Rheum Dis. 2014;73:551–556. doi: 10.1136/annrheumdis-2012-201807.
    1. World Medical Association (WMA) (2008) Declaration of Helsinki. Seoul: WMA. Accessed 8 November 2013
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health survey 1.0. Health Econ. 1993;2:217–227. doi: 10.1002/hec.4730020305.
    1. Van der Zee KI, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding [measuring general health status with the RAND-36, user manual] Groningen: Northern Center of Health Care Research; 1994.
    1. Van der Zee KI, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status. Int J Behav Med. 1996;3:104–122. doi: 10.1207/s15327558ijbm0302_2.
    1. Ware JE, Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol. 1998;51:903–912. doi: 10.1016/S0895-4356(98)00081-X.
    1. Moorer P, Suurmeije TP, Foets M, Molenaar IW. Psychometric properties of the RAND-36 among three chronic diseases (multiple sclerosis, rheumatic diseases and COPD) in The Netherlands. Qual Life Res. 2001;10:637–645. doi: 10.1023/A:1013131617125.
    1. Bulliger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA project. Soc Sci Med. 1995;41:1359–1366. doi: 10.1016/0277-9536(95)00115-N.
    1. Alonso J, Prieto L, Ferrer M, et al. Testing the measurement properties of the Spanish version of the SF-36 Health Survey among male patients with chronic obstructive pulmonary disease. J Clin Epidemiol. 1998;51:1087–1094. doi: 10.1016/S0895-4356(98)00100-0.
    1. Lopes FP. Creation of the Portuguese version of MOS SF-36 part II—validation tests. Acta Med Port. 2000;13:119–127.
    1. Perneger TV, Leplège A, Etter JF, Rougemont A. Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults. J Clin Epidemiol. 1995;48:1051–1060. doi: 10.1016/0895-4356(94)00227-H.
    1. Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum. 2005;53:5–11. doi: 10.1002/art.20910.
    1. Jason L, Brown M, Evans M, et al. Measuring substantial reductions in functioning in patients with chronic fatigue syndrome. Disabil Rehabil. 2011;33:589–598. doi: 10.3109/09638288.2010.503256.
    1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study group. Ann Intern Med. 1994;121:953–959. doi: 10.7326/0003-4819-121-12-199412150-00009.
    1. Van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology. 2010;49:1294–1302. doi: 10.1093/rheumatology/keq043.
    1. Segal B, Thomas W, Rogers T, et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum. 2008;59:1780–1787. doi: 10.1002/art.24311.
    1. Kirwan J, Minnock P, Adebajo A, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol. 2007;34:1174–1177.
    1. Davies H, Brophy S, Dennis M, Cooksey R, Irvine E, Siebert S. Patient perspectives of managing fatigue in ankylosing spondylitis, and views on potential interventions: a qualitative study. BMC Musculoskelet Disord. 2013;14:163. doi: 10.1186/1471-2474-14-163.
    1. Prins JB, Van der Meer JWM, Bleijenberg G. Chronic fatigue syndrome. Lancet. 2006;367:346–355. doi: 10.1016/S0140-6736(06)68073-2.
    1. Razavi D, Gandek B. Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. J Clin Epidemiol. 1998;51:975–981. doi: 10.1016/S0895-4356(98)00089-4.
    1. Sprigg N, Gray LJ, Bath PM, et al. Quality of life after ischemic stroke varies in western countries: data from the Tinzaparin in Acute Ischaemic StrokeTrial (TAIST) J Stroke Cerebrovasc Dis. 2012;21:587–593. doi: 10.1016/j.jstrokecerebrovasdis.2011.01.007.
    1. Wagner AK, Gandek B, Aaronson NK, et al. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:925–932. doi: 10.1016/S0895-4356(98)00083-3.
    1. Macinko J, Starfield B, Shi L. The contribution of primary care systems to health outcomes within Organization For Economic Cooperation and Development (OECD) countries, 1970–1998. Health Serv Res. 2003;38:831–865. doi: 10.1111/1475-6773.00149.
    1. Assi J, Lucchini M, Spagnolo A. Mapping patterns of well-being and quality of life in extended Europe. Int Rev Econ. 2012;59:409–430. doi: 10.1007/s12232-012-0147-z.
    1. Ware NC, Kleinman A. Culture and somatic experience: the social course of illness in neurasthenia and chronic fatigue syndrome. Psychosom Med. 1992;54:546–560. doi: 10.1097/00006842-199209000-00003.
    1. Nicklin J, Cramp F, Kirwan J, Greenwood R, Urban M, Hewlett S. Measuring fatigue in rheumatoid arthritis: a cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. Arthritis Care Res. 2010;62:1559–1568. doi: 10.1002/acr.20282.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir